VitaDX

This technology, based on research carried out by researchers from the Institute of Molecular Sciences in Orsay (ISMO, UMR CNRS and Université Paris-Sud) and practitioners at CHU Bicêtre (AP-HP), aims to diagnose bladder cancer earlier and more reliably. VitaDX started its first clincal trial in january 2017 and obtained the CE marking for its first. VitaDX is currently developing a medical software solution for early diagnosis of bladder cancer using fluorescence imaging and machine learning.